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ABSTRACT
PTEN loss and constitutive activation of the class I phosphoinositide 3-kinase 
(PI3K) pathway are key drivers of endometrial tumorigenesis. In some cancer types, 
PTEN-deficient tumors are reliant on class I PI3K p110β (encoded by PIK3CB) activity 
but little is known about this contribution in endometrial tumorigenesis. In this 
study, we find that p110β is overexpressed in a panel of 7 endometrial cancer cell 
lines compared to non-transformed cells. Furthermore, in 234 clinically annotated 
patient samples, PIK3CB mRNA levels increase significantly in the early phase of 
tumorigenesis from precursors to low grade primary malignant lesions whereas 
PIK3CA levels are higher in non-endometrioid compared to endometrioid primary 
tumors. While high levels of either PIK3CA or PIK3CB associate with poor prognosis, 
only elevated PIK3CB mRNA levels correlate with a high cell cycle signature score 
in clinical samples. In cancer cell lines, p110α  inhibition reduces cell viability by 
inducing cell death in PIK3CA mutant cells while p110β inhibition delayed proliferation 
in PTEN-deficient cells, but not in WT cells. Taken together, our findings suggest that 
PIK3CB/p110β contributes to some of the pleiotropic functions of PI3K in endometrial 
cancer, particularly in the early steps by contributing to cell proliferation.
INTRODUCTION
The class I phosphoinositide 3-kinase (PI3K) 
pathway is frequently altered in cancer via genetic 
alterations in several gene pathway members, 
contributing to uncontrolled cell proliferation and 
survival [1, 2]. Class IA consists of heterodimers of 
catalytic subunits (p110α, p110β and p110δ encoded 
by PIK3CA, PIK3CB and PIK3CD respectively) and 
adaptor proteins (p85α and p85β encoded by PIK3R1 
and PIK3R2 respectively) [3] which phosphorylate 
phosphatidylinositol (4,5)-bisphosphate (PtdIns(4,5)P2) to 
phosphatidylinositol (3,4,5)-trisphosphate (PtdIns(3,4,5)
P3). This reaction is opposed by PTEN (phosphatase and 
tensin homolog), which de-phosphorylates PtdIns(3,4,5)
P3 to PtdIns(4,5)P2, hence limiting the effects of class I 
PI3K activity [4]. In cancer, activating PIK3CA mutations 
are frequent [5, 6] while PIK3CB is mutated less often. 
So far, two activating mutations in PIK3CB have been 
characterized [7, 8], one of which has been discovered 
in a few cancer types by whole exome sequencing [8]. 
p110β can however promote oncogenic transformation 
when over-expressed [9] and has also been shown to 
be the key isoform mediating tumorigenesis in PTEN-
deficient breast and prostate cancers [10-14]. A study by 
Juric et al further highlighted the importance of p110β 
in tumorigenesis [15] by showing that PIK3CA mutant 
tumors, which were initially sensitive to p110α inhibition, 
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eventually developed resistance due to acquired loss of 
PTEN. Resistance to p110α inhibition could however 
be overcome when treatment with a p110β inhibitor was 
introduced. Other studies have however shown that certain 
tissues with PTEN loss become dependent on p110α rather 
than p110β [16]. These contrasting studies indicate the 
importance of studying isoform-dependence associated 
with PTEN-loss in each tissue as this may have significant 
therapeutic implications.
Endometrial cancer is the most common 
gynecological malignancy in developed countries. 
Endometrial tumors have been traditionally divided 
into two groups, type I and type II, according to 
clinical, pathologic and molecular features. About 80% 
of diagnosed cases are comprised of the histologic 
subtype endometrioid endometrial cancer (EEC) and are 
classified as type I. These tumors are more often estrogen-
dependent, linked to obesity, low grade and stage and with 
good prognosis if treated early. On the other hand, type 
II, or non-endometrioid endometrial cancer (NEEC), are 
usually estrogen-independent with serous, clear cell or 
undifferentiated morphology, high grade and stage and 
with poor prognosis. Recent whole exome sequencing 
and integrative genomic profiling led to a molecular-based 
sub-classification of EEC and NEEC tumors [17-19]. The 
PI3K pathway is the most frequently altered pathway in 
EEC with more than 80% of tumors harboring somatic 
alterations in at least one gene member of the pathway, 
including high frequency mutations in PTEN, PIK3CA 
and PIK3R1 and low frequency in AKT and PIK3R2 [20-
22]. Loss-of-function mutation of the tumor suppressor 
gene PTEN is the most common genetic event in EEC 
and occurs as an early event in 18-50% of lesions with 
atypical hyperplasia [23-25]. PIK3CA is frequently 
mutated in 10-39% of EEC but in contrast to PTEN has 
a higher frequency in high grade, aggressive, invasive 
and less differentiated tumors [24, 26, 27]. PIK3CA gene 
amplification can also account for other mechanisms for 
PI3K pathway activation and was found to correlate with a 
PI3K activation profile which segregated more frequently 
to a group of aggressive and invasive tumors, notably in 
NEECs. In contrast to PIK3CA, mutation events are rare 
in PIK3CB with 2.3% in endometrial cancer according 
to data from COSMIC (release v72 http://cancer.sanger.
ac.uk/cosmic [28], including a recently characterized 
oncogenic mutation in its catalytic domain [8]). PIK3CB 
mRNA levels were found to be elevated in endometrial 
tumors compared to normal tissue in a few patient 
samples [29]. Overexpression of the p110β isoform is 
thus a possible explanation for the oncogenic properties 
of the wild type form of this isoform, but this is largely 
unknown particularly in endometrial cancer. Considering 
that PTEN loss and PI3K pathway activation are known 
key drivers of carcinogenesis in endometrial cancer, we 
hypothesized that p110β could play a significant role 
particularly in PTEN-deficient tumors. We therefore 
explored the cellular function and signaling properties of 
p110β compared to those of p110α in a panel of PTEN-
positive and PTEN-deficient endometrial carcinoma cell 
lines. Finding that the protein levels of p110β, but not 
p110α, were upregulated in most endometrial carcinoma 
cell lines, we then demonstrated the distinct contribution 
of p110α and p110β to cell survival, proliferation and 
signaling depending on the presence of PTEN and PIK3CA 
mutations, using selective pharmacological inhibitors. 
Furthermore, the potential clinical relevance for these 
findings were substantiated by exploring an extensively 
clinically annotated patient cohort with 234 samples 
ranging from precursors through different stages of 
dedifferentiation during tumorigenesis demonstrating an 
increase in PIK3CB mRNA levels in early endometrioid 
lesions that associated with a high cell cycle progression 
score and decreased survival.
RESULTS
p110β levels are elevated in endometrial cancer 
cell lines and increase from precursors to invasive 
lesions in clinical samples correlating with 
reduced survival
We have examined the protein levels of the class I 
PI3K catalytic (p110α and p110β) and regulatory subunits 
(p85α and p85β), PTEN, Akt and phosphorylated Akt on 
serine 473 (p-S473-Akt) and threonine 308 (p-T308-Akt) 
in whole cell extracts of 7 endometrial cancer cell lines 
versus a non-tumor immortalized endometrial cell line 
(EM). In actively growing cells, the levels of p110β were 
elevated in endometrial cancer cell lines compared to EM 
cells, independently of their mutational status, whereas the 
levels of p110α demonstrated less change (Figure 1A-1B). 
The levels of p85α in the cancer cells were comparable to 
EM cells but lower levels of p85β were observed in several 
of the cancer cell lines. To determine the PI3K signaling 
status, we examined the levels of p-S473-Akt and p-T308-
Akt versus total Akt in actively growing cells (Figure 1C). 
Consistent with other studies [30], all cell lines with PTEN 
mutations (MFE-296) and exhibiting protein loss (MFE-
319, RL-95-2 and Ishikawa) displayed high p-Akt levels 
(Figure 1C-1D – c.f. quantifications in Supplementary 
Figure S1). Interestingly, MFE-280 cells, which express 
PTEN but harbor mutations in PIK3CA, demonstrated low 
levels of p-S473/T308-Akt (Figure 1C-1D), consistent 
with the notion that PTEN loss and PIK3CA mutation 
can have different effects on Akt activation. Low p-Akt 
levels have previously been observed in breast cancer cell 
lines with PIK3CA mutations, demonstrating possible 
Akt-independent effects of some mutations in PIK3CA 
[31-33]. We also analyzed the mRNA levels of PIK3CB 
compared to PIK3CA in a cohort of endometrial cancer 
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patients, including 18 with complex atypical hyperplasia 
(CAH), 174 primary tumors and 42 metastatic lesions. 
PIK3CB mRNA levels were significantly increased from 
precursor lesions with CAH to grade 1 EEC lesions and 
remained constant in higher grades, NEEC and metastatic 
tumors (Figure 2A). These results suggest that increased 
levels of PIK3CA/p110β contribute to the early phase of 
endometrial tumorigenesis. In contrast, a distinct pattern 
was seen for PIK3CA mRNA levels being significantly 
elevated in NEEC (Figure 2B). Furthermore, elevated 
levels of both PIK3CA and PIK3CB were also reflected in 
lower disease specific survival (Figure 2C-2D).
PIK3CA mutant endometrial cancer cells respond 
to p110α inhibition by a decrease in cell survival
PTEN-deficient cancer cells have been suggested 
to rely upon p110β signaling for their sustained cell 
proliferation and tumorigenesis [10, 13]. To investigate 
whether endometrial cancer cell functions are also 
influenced by PTEN expression status and if they are 
dependent upon p110α and/or p110β, we evaluated the 
cell viability of PTEN-positive (EM, KLE and MFE-280) 
and PTEN-deficient cell lines (MFE-319 and RL95-2) 
following treatment with the selective p110α (A66) and 
p110β (TGX-221) inhibitors (Figure 3A) [34]. Inhibition 
of p110α had no effect in PTEN-deficient cells and had 
only a marginal effect in KLE and EM cells with WT 
PTEN. In contrast, a dose-dependent decrease in cell 
viability was induced in MFE-280 cells harboring an 
activating mutation in PIK3CA (H1047Y), reaching an 
SF50 (50% surviving cell fraction) at < 1 µM. All cell lines 
had little response to inhibition of p110β with TGX-221 
and required ≥ 10 µM to reach an SF50. To investigate if 
the observed decrease in cell viability in MFE-280 cells 
was due to an induction of apoptosis, cells were analyzed 
by Western immunoblotting for poly(ADP-ribose) 
polymerase 1 (PARP) cleavage following treatment with 
A66 and TGX-221 (Figure 3B-3C). Incubation with A66 
and TGX-221 had no effect in KLE, MFE-319 or RL95-2 
cells on PARP cleavage (Figure 3B and Supplementary 
Figure 1: p110β levels are elevated in endometrial cancer cell lines. A. and C. Whole cell extracts obtained from actively 
growing cells analyzed by Western immunoblotting with the indicated antibodies. α-tubulin was used as a loading control. § indicate 
PIK3CA mutant cell lines. * indicate a non-specific band. B. p110β/α-tubulin and p110α/α-tubulin ratios shown as fold increase compared 
to EM cells from 3-4 independent experiments with standard deviations. D. Chart showing the mutational status of each gene and for each 
cell line (gray, WT; black, mutated gene).
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Figure S2A-B). In contrast, PARP cleavage was induced 
by A66 in a dose-dependent manner in MFE-280 cells as 
cleavage was apparent at 1 µM and more strongly at 10 
µM (Figure 3B-3C). Inhibition of p110β with TGX-221 
had a much weaker effect on PARP cleavage in these cells 
(Figure 3B-3C). Interestingly, A66 and TGX-221 induced 
similar effects on the production of high molecular weight 
DNA fragments but without the generation of oligosomal 
DNA fragments (Figure 3D), perhaps indicative of the 
induction of an alternative type of cell death as previously 
observed in other studies [35-37]. These results suggest 
that p110α inhibition preferentially triggers a decrease in 
cell viability and induces cell death in PIK3CA mutant 
MFE-280 cells, and not in PIK3CA WT KLE cells. PTEN-
deficient cells were in contrast resistant to both p110α and 
p110β inhibition.
p110β inhibition impairs cell proliferation in 
PTEN-deficient cells but with variable responses
p110β has previously been shown to regulate cell 
proliferation [10, 38] particularly in PTEN-deficient 
tumors [13]. Since p110β inhibition did not induce PARP 
cleavage in PTEN-deficient cells, we tested if an effect 
could be apparent on cell proliferation, using the highest 
concentration of TGX-221 (10 µM) which showed a 50% 
decrease in cell viability in some cell lines (Figure 3A). 
While no significant decrease in cell number was observed 
for the PTEN-positive cell lines, p110β inhibition induced 
Figure 2: PIK3CB mRNA levels increase from precursors to low grade endometrial carcinoma lesions which associates 
with lower survival. Box-plots showing PIK3CB A. and PIK3CA B. mRNA levels in relation to histological type and grade. Significant 
Kruskall Wallis test p-values are given above the relevant box plots. CAH: Complex atypical hyperplasia (n = 18). Endometrioid grade 1 
(n = 48), grade 2 (n = 53), grade 3 (n = 39). NEEC: Non endometrioid endometrial carcinoma (n = 34). Mets: Metastatic lesions (n = 42). 
Kaplan-Meier survival curves shown for patients with high, medium and low mRNA levels according to tertile limits for PIK3CB C. and 
PIK3CA D. Numbers in brackets represent number of disease specific deaths in each group.
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a significant decrease in the number of cells in the PTEN-
deficient cell lines RL95-2 and MFE-319 following 4 and 
3 days of treatment respectively (Figure 4A). However, 
after 4 days of treatment, the cell division rate of MFE-319 
cells returned to that of control cells. This was reflected 
by a significant increase in total doubling time in RL95-2 
Figure 3: PIK3CA mutation and PTEN expression status influence differently the sensitivity of p110α and p110β 
inhibitors to cell survival in endometrial carcinoma cells. A. Cell viability determined by MTS assay in PTEN-positive (PTEN+) 
(EM, KLE and MFE280) and PTEN-deficient (PTEN-) cell lines (RL95-2 and MFE-319) of which only MFE-280 harbor mutated PIK3CA 
(§), treated with 0.01-10 µM of A66 or TGX-221 for 72 h. Data is presented for each cell line as a % relative to DMSO control (mean of 3 
independent experiments in triplicates + SDs). Surviving cell fraction of 50% (SF50) threshold is indicated as a black line. B. Whole cell 
extracts were obtained from cells treated with 10 µM of the p110α inhibitor A66 or p110β inhibitor TGX-221 for 24 h and analyzed by 
Western immunoblotting for PARP cleavage and α-tubulin levels. C. Whole cell extracts were obtained from MFE-280 cell treated with 
0.01-10 µM of A66 or TGX-221 and 0.5 µM PIK-75 for 24 h and analyzed by Western immunoblotting for PARP cleavage and α-tubulin 
levels. D. Agarose electrophoresis of high molecular weight DNA fragmentation of MFE-280 floating cells collected following treatment 
with 1-10 µM of A66 or TGX-221 and 0.5 µM PIK-75 for 24 h.
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but not in MFE-319 cells following TGX-221 treatment 
(Figure 4B). p110β has also been shown to contribute 
to G1 to S phase progression [39, 40] and we therefore 
evaluated if p110β inhibition affected the cell cycle 
distribution of the PTEN-deficient cells. As shown in 
Figure 4C, RL95-2, but not MFE-319 cells, demonstrated 
an increase in the percentage of cells in G1 phase and a 
concomitant decrease in the percentage of cells in S and 
G2/M phases compared to control cells. These results 
demonstrate that p110β can contribute to cell proliferation 
by regulating G1 to S phase progression to a certain extent 
but only in a subset of PTEN-deficient cells.
High PIK3CB mRNA levels correlate with a high 
cell cycle progression gene signature score in 
clinical samples
To further explore the clinical relevance of the 
observed contribution of p110β activity in cell proliferation 
in cell line studies, we analyzed potential phenotypic links 
between mRNA levels of both PIK3CB and PIK3CA in 
clinically annotated endometrial carcinoma samples with a 
cell cycle progression (CCP) score established from 31 CC 
genes [41]. High PIK3CB mRNA levels were significantly 
associated with high level of CCP signature score and 
high protein levels of the proliferation cell nuclear antigen 
(PCNA) for all primary tumors and notably within the 
endometrioid subgroup (Figure 5A-5B). In contrast, 
Figure 4: Inhibition of p110β delays cell proliferation in PTEN-deficient endometrial cancer cells. A. Cell lines were plated 
at day 0 and treated with DMSO (black line) or with 10 µM TGX-221 (grey line) at day 1 and day 3 and the number of cells were counted 
at all the indicated days. Cell numbers are presented as means of 3 independent experiments in triplicates for each day + SDs, t-test, * P < 
0.05. The PIK3CA mutant cell line MFE-280 is marked with §. B. Doubling time calculated from data acquired in (A) for each cell line. C. 
MFE-319 and RL95-2 cells were treated with DMSO or 10 µM TGX-221 for 24 h and the percentage of cells in each phase of the cell cycle 
was determined by flow cytometry. Data are means +/- SDs of 3-4 independent experiments and Student’s t tests were performed comparing 
TGX-221-treated cells to DMSO-treated cells for each cell cycle phase with ** P < 0.01 and *** P < 0.001.
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PIK3CA mRNA levels did not associate with measures for 
cell proliferation when explored for all primary tumors or 
the endometrioid subgroup (Figure 5C-5D). These results 
suggest that PIK3CB/p110β contributes to endometrial 
tumorigenesis by influencing the cell cycle regulation of 
endometrial cancer cells. In contrast, poor disease specific 
survival observed with high PIK3CA levels (Figure 2D) is 
more likely due to other PI3K-mediated cellular processes 
than proliferation.
PTEN positive and deficient endometrial cancer 
cells respond differently to p110α and p110β 
inhibition on Akt and S6 signaling
To correlate cellular function with PI3K pathway 
signaling, we determined the effect of both p110α and 
p110β inhibitors on AKT (p-S473-Akt) and mTORC1 (p-
S240/S244-S6) signaling (Figure 6). All cell lines, whether 
PTEN-positive with low p-S473-Akt or PTEN-deficient 
with high p-S473-Akt, responded to p110α inhibition with 
a decrease in Akt basal activity. Interestingly, the best 
response to p110α inhibition, measured both by decreased 
p-Akt and cell viability, was observed in the PIK3CA 
mutant MFE-280 cells. Inhibition of p110β also led to 
a decrease in p-S473-Akt in all cells except the PTEN-
deficient cell line MFE-319. Response to p110α inhibition 
on S6 signaling was varied from a low response in PTEN-
positive cells to no response at all in PTEN-negative cells. 
Response to p110β inhibition on S6 signaling was even 
more varied and independent of PTEN expression status. 
The PTEN-deficient RL95-2 cells were responsive while 
MFE-319 cells were resistant. The PTEN-positive cells 
KLE were very responsive while MFE-280 cells were 
resistant.
DISCUSSION
All class I PI3K isoforms can produce PtdIns(3,4,5)
P3, the levels of which are controlled by at least the action 
of PTEN. In lesions with loss of PTEN, tumorigenicity is 
thought to rely on the activity of not only p110β but also 
of p110α depending on the tissue type [10, 13, 16, 42]. 
Figure 5: High PIK3CB mRNA levels associates with high cell proliferation markers in primary tumors. Box-plots are 
shown for the cell cycle progression (CCP) signature score in relation to low versus high PIK3CB A. or PIK3CA mRNA levels C. and for 
PCNA protein levels in relation to low versus high PIK3CB B. or PIK3CA mRNA levels D., either in all primary tumors or endometrioid 
subgroup tumors.
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In EEC, PTEN is the most commonly mutated gene [43] 
but little is known however about the exact contribution 
of p110β in endometrial tumor development particularly 
in relation to PTEN loss. In this study, we demonstrate 
that p110β is highly expressed in endometrial cancer cell 
lines and that its mRNA levels increase in clinical samples 
during the initial steps of endometrial carcinogenesis 
for the endometrioid subtype. In contrast, high PIK3CA 
mRNA levels were observed in non-endometrioid tumors, 
which would appear to be consistent with previous 
findings linking PIK3CA gene amplification to aggressive 
endometrial tumors of non-endometrioid histology [44]. In 
addition, different roles were found for the two isoforms in 
this study, as supported by the association of high mRNA 
levels of PIK3CB, but not PIK3CA, with markers for high 
proliferation (CCP score and PCNA levels), notably in 
endometrioid tumors. Interestingly, the CCP score was 
reported to increase early in grades 1 and 2 compared to 
CAHs [45], at the same stage of tumor development when 
PIK3CB mRNA levels are found to be increased in this 
study. Hence, high PIK3CB mRNA levels may provide a 
proliferative advantage in early stages of tumorigenesis. 
Using pharmacological inhibition of p110β, our cell line 
studies also pointed to a role for p110β in cell proliferation 
since its inhibition delayed cell proliferation by arresting 
cells in G1 in a PTEN-deficient cancer cell line, RL95-
2. Consistently, p110β has previously been shown to be 
localized in the nucleus [40, 46, 47] and to mediate S phase 
entry, control DNA replication and loading of PCNA on 
chromatin [40]. In functional studies of nuclear p110β [40, 
48], TGX-221 was previously used at high concentration 
(30 µM), which was shown to be specific for p110β and 
not p110α [40]. In this study, inhibition of proliferation 
was only apparent with 10 µM of the inhibitor, which may 
be due to high levels of p110β in endometrial cancer cell 
lines as well as its subcellular localization spanning not 
only the cytoplasm but also the nucleus in other cell lines 
[46, 47] and the endometrial cancer cells used in this study 
(data not shown). Although we cannot exclude off-target 
effects at 10 µM, an extensive study of TGX-221 at that 
concentration on a large panel of lipid and protein kinases 
by Jamieson et al showed high specificity for p110β [34].
The reported association between p110β level and 
activity with cell proliferation suggests further clinical 
testing of endometrial tumors with PTEN mutations 
for potential benefit from p110β selective inhibitors to 
delay tumor growth. This is also particularly relevant in 
light of a recent study showing response to inhibition of 
p110β in PTEN-deficient breast cancer cells, resistant to 
p110α inhibition [15]. However, we observed that PTEN-
deficient cancer cells can respond with different efficacy 
following p110β inhibition (MFE-319 versus RL95-2 
cells) and resistance to treatment was observed in MFE-
319 cells (Figure 4). This would be consistent with a 
recent study by Schwartz et al showing that p110α was 
reactivated following p110β selective inhibition in PTEN-
deficient cells [49]. The efficacy of p110β inhibition may 
hence have limited durability and combined or sequential 
treatment targeting p110β and p110α may be necessary in 
tumors with PTEN loss. Other genetic factors may also 
Figure 6: Heterogeneous response on Akt and S6 signaling following p110α and p110β inhibition. A. Whole cell extracts 
were obtained from cells treated with 10 µM of A66 or TGX-221 for 24 h and analyzed by Western immunoblotting for pS473 Akt, Akt, 
pS240/244 S6 ribosomal protein (short and long exposures are shown), S6 and α-tubulin levels. B. Quantification of pS473-Akt/Akt and 
pS240/244-S6/S6 ratios relative to DMSO-treated controls for each cell line from at least 3 independent experiments. Standard deviations 
and significance level for difference (T-test compared to DMSO-treated cells: *P < 0.05, **P < 0.01, ***P < 0.001) are shown for each 
condition.
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influence the efficacy of p110β inhibition, such as the 
presence of RAS mutations, since the RAS-MEK and PI3K 
pathways are known to converge [50]. Indeed RL95-2 cells 
harbor an activating mutation in H-Ras (Q61H), which 
may explain the necessity of high concentration of TGX-
221. PTEN-deficient cells with RAS mutation may benefit 
from a combination of p110β and RAS/MEK pathway 
inhibition. The cause for resistance to p110β inhibition in 
MFE-319 cells is not yet known but it is worth noticing 
that these cells harbor a mutation in the fibroblast growth 
factor receptor 2 (S252W) shown previously to be 
oncogenic and to occur with high frequency in endometrial 
cancer [51, 52]. However, although FGFR signaling is 
known to activate the PI3K pathway, MFE-319 cells were 
shown to be insensitive to FGFR inhibition [53]. In any 
case, identifying the molecular mechanisms of resistance 
to p110β inhibition in a subset of PTEN-deficient tumors 
is crucial to design clinical therapeutic strategies with 
long-term efficacy. In addition, this would anticipate 
understanding of the results of a phase I/IIa clinical trial 
with a selective p110β inhibitor in carcinomas with PTEN 
loss, including endometrial cancer (NCT01458067) and 
which has recently been completed [54].
The PTEN-positive MFE-280 cells harboring a 
PIK3CA mutation in its catalytic domain (H1047Y) 
responded to selective p110α inhibition with a decrease in 
cell viability and an increase in cell death while PIK3CA 
WT and PTEN-deficient cell lines were resistant. The 
observation that these cells were more sensitive to p110α 
inhibition than WT PIK3CA is in agreement with the 
studies of Torbett et al [12] showing that breast cancer 
cells with PIK3CA mutations in their catalytic domain 
responded to the p110α inhibitor PIK-75, but not PTEN-
deficient cells. Consistently, T47D breast cancer cells with 
the H1047R mutation in PIK3CA were sensitive to the 
p110α inhibitor BYL719 measured by cell viability assay, 
but exhibited a lower response when PTEN was knocked 
down [15]. We also showed that inhibition of p110β had 
little effect on cell viability and required >10 µM TGX-
221 to reach 50% cell survival in most endometrial cancer 
cell lines studied, including PTEN-deficient cells. This 
is in agreement with the work of Weigelt et al [30] in 
endometrial cancer cells but in contrast to studies in breast 
and prostate cancer [10, 11, 13], arguing that p110β does 
not contribute to cell survival in endometrial cancer cells. 
In this study, we showed that the PIK3CA mutant cell 
line MFE-280 reached an SF50 of 10 µM in cell viability 
assay and was the only cancer cell line where TGX-221 
induced cell death, albeit weakly, and only at the highest 
dose at 10 µM, hence with low efficacy. This may suggest 
an active cooperation between p110α and p110β. A recent 
study has indeed showed that following serum stimulation, 
activated p110α associates with a fraction of p110β and 
leads to p110β activation [55]. Accordingly, the activating 
mutation in PIK3CA found in MFE-280 cells may allow 
the recruitment of p110β to p110α and its subsequent 
activation. The resulting activation of both isoforms would 
hence allow these cells to respond to inhibitors selective 
for either isoform. The association of p110β with p110α 
would implicate that both isoforms can engage in similar 
cellular function, in this case cell survival, and respond to 
similar external cues. On the other hand, the remaining 
fraction of p110β not associated with p110α could still 
engage in other cellular functions including proliferation.
Different effects on PI3K isoform-specific signaling 
were demonstrated to be PTEN context dependent for 
p110α and p110β selective inhibition. Decrease in p-Akt 
was observed with variable efficacy with both p110α 
and p110β inhibitors, independently of PTEN status 
and despite their differential effects on cell viability. In 
contrast, a different response to p110α inhibition was 
apparent for p-S6 which was lower in PTEN-positive 
but not in PTEN-deficient cells. This would be consistent 
with a study in breast cancer cells where persistence of 
mTORC1 signaling via p-S240/S244-S6 was shown to be 
a marker of resistance to p110α inhibition [56] although 
this study did not show any correlation with PTEN 
status. p110β inhibition decreased p-S6 in RL95-2 cells 
but not in MFE-319 displaying a more transient effect 
of p110β inhibition on cell proliferation. The difference 
in mTORC1/S6 signaling sensitivity to p110β inhibition 
in PTEN-deficient cells seemed to be correlated with 
the difference in p-S6 levels, i.e. with a higher response 
in RL95-2 cells that have the lowest p-S6 levels and no 
response in MFE-319 with the highest levels. In addition, 
decrease in p-S6 by p110β inhibition correlated with a 
decrease in cell proliferation in RL95-2 cells. MFE-319 
cells may thus have acquired resistance to both p110α and 
p110β inhibitors via mTORC1 hyper-activation.
In conclusion, our results demonstrate for the first 
time that high levels of PIK3CB/p110β associate with the 
early stages of endometrial tumorigenesis and increased 
cell proliferation, suggesting a proliferative advantage. In 
cell lines, p110β plays a role in a PTEN-dependent context 
in cell proliferation but not in cell survival. However, the 
benefits of p110β inhibition may not be lasting and lead 
to resistance in some PTEN-deficient endometrial tumors. 
This may be relevant for the design of more effective 
and combined targeted therapy in future clinical trial in 
endometrial cancer featuring loss-of-function mutations 
in PTEN.
MATERIALS AND METHODS
Reagents
Antibodies used in Western immunoblotting are the 
following: anti-Akt (2920), -S473-Akt (9271), -pT308-
Akt (C31E5E), -p110α (4249), -p110β (3011), -PARP 
(2730), -S6 (2217) and -pS240/S244-S6 (5364) from Cell 
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Signaling; anti-p85α (05-212) from Millipore; anti-p85β 
(S3089) from Epitomics; anti-PTEN (7974) from Santa 
Cruz and anti-α-tubulin (T5168) from Sigma-Aldrich. 
Horse radish peroxidase-conjugated secondary antibodies 
were from Life Technologies. The PI3K selective 
inhibitors targeting p110α were from Selleck Chemicals 
(A66) and Millipore (PIK-75) and targeting p110β (TGX-
221) from Cayman chemicals [34, 57].
Cell lines and cell culture conditions
Seven endometrial cancer cell lines were chosen to 
represent different status for PI3K/Akt pathway activation 
and PTEN protein expression, as shown in this study and 
by others [21, 30, 43, 58]. Cancer cell lines were obtained 
from ATCC (KLE, RL95-2), DSMZ Germany (MFE-296, 
MFE-319, EFE-184 and MFE-280) and Sigma-Aldrich 
(Ishikawa). EM-E6/E7-hTERT (EM), a non-transformed 
endometrial cell line isolated from glandular endometrial 
tissue and immortalized with E6/E7 and human TERT 
[59, 60], was a gift from Prof PM Pollock (University of 
Queensland, Australia). All cancer cells were authenticated 
by short tandem repeat (STR) DNA profiling (IdentiCell 
Service, Dept. Molecular Medicine, Aarhus University 
Hospital, Denmark for all cancer cell lines). EM cells were 
confirmed to have a unique STR profile as shown in Table 
1 (MD Anderson Cancer Center, USA). All cancer cells 
were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% fetal bovine serum 
(FBS) and antibiotics (100 IU/ml penicillin and 100 μg/ml 
streptomycin). EM cells were cultured in DMEM/Ham’s 
F12 supplemented with Insulin-Transferrin-Selenium, 
10% FBS and antibiotics and changed to DMEM 
containing 10% FBS and antibiotics 24 h before harvest. 
Cells were harvested when they reached a maximum of 
80% confluence.
Cell viability assay, cell counts and flow cytometry
For cell viability, cells were seeded in 96-well 
plates with 1000 or 3000 cells/well depending on the 
cell line, grown for 24 h and treated with inhibitors 
for 72 h. Cells were then assayed with the CellTiter 96 
AQueous One Solution Cell Proliferation Assay (Promega) 
by incubation with 20 µL of 3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium for 1 h and reading at 490 nm. For cell 
counts, cells were plated in 6-well plates, grown for 24 h, 
treated and counted following trypsinization at the same 
time point every day with a BioRad TC10 automated 
cell counter. For flow cytometry, 2 x105 cells were 
seeded in 6-well plates, treated for 24 h and processed 
as described previously [61]. DNA was stained with 100 
μg/mL propidium iodide and the cell cycle distribution 
was analyzed using a BD Biosciences Accuri C6 flow 
cytometer. For DNA fragmentation assays, cells were 
plated in 6-well plates, treated for 24 h and the floating 
cells were collected, lysed in 40 µL DMSO and 40 µL 
Tris-EDTA pH 7.4 supplemented with 2% SDS, according 
to Suman et al [62] and half was loaded on a 2% agarose 
gel.
Whole cell extracts, subcellular fractionation and 
Western immunoblotting
Whole cell extracts were prepared in 
radioimmunoprecipitation assay (RIPA) lysis buffer (50 
mM Tris pH 8.0, 0.5% deoxycholic acid, 150 mM NaCl, 
1% NP-40, 0.1% SDS) supplemented with 5 mM NaF, 2 
mM Na3VO4 and 1x Sigma Protease Inhibitor Cocktail. 
Subcellular fractionation was carried out according to 
O’Caroll et al. [63] and nuclear pellets were lysed in 
RIPA. RL95-2 cells required an additional syringing 
step of the nuclear pellet resuspended in wash buffer 
to avoid cytoplasmic contamination. Equal amount of 
proteins were resolved by SDS-PAGE, immunoblotted 
as described previously [64] and detected by enhanced 
chemiluminescence using the SuperSignal West Pico 
Chemiluminescent Substrate (Pierce) and visualized with 
a BioRad ChemiDocTM Xrs+.
Patient series
Fresh frozen tissue was collected from patients 
diagnosed with endometrial cancer at Haukeland 
University hospital during the period from 2001-2013 and 
include a total of 234 clinical samples with 18 endometrial 
cancer precursor lesions (CAH), 174 primary tumors and 
42 metastases. Clinical data were collected as described 
earlier [25, 45]. The patient cohort used for p110β 
immunohistochemistry is described in detail in Tangen et 
Table 1: STR profile of EM-E6/E7-hTERT cells
Marker Allele(s)
AMEL X
 CSF1PO 11,12
 D13S317 8,9
 D16S539 10,11
 D18S51 15
 D21S11 31.2,32
 D3S1358 15,17
 D5S818 12,13
 D7S820 10,12
 D8S1179 10,13
 FGA 21,23
 TH01 6,7
 TPOX 8,11
 vWA 14
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al [45]. This study was conducted in line with Norwegian 
legislation and international demands for ethical review, 
approved by the Norwegian Data Inspectorate, Norwegian 
Social Sciences Data Services and the Western Regional 
Committee for Medical and Health Research Ethics 
(NSD15501; REK 052.01). Patients signed an informed 
consent form.
Microarray analyses and reverse phase protein 
array
Fresh frozen tissue collected in parallel from 18 
CAH, 174 primary and 42 metastatic lesions was used 
for RNA extraction as previously reported [25, 45]. The 
majority of samples had tumor purity above 80% with 
a threshold inclusion set at >50%. Samples were gross 
dissected when necessary to achieve this level of tumor 
purity. mRNA was extracted from fresh frozen tissue 
using the RNeasy Mini Kit (Qiagen). Samples were 
hybridized to Agilent Whole Human Genome Microarrays 
(G4112F), scanned and normalized as previously reported 
[65]. mRNA values for PIK3CA (probe A_23_P92057) 
and PIK3CB (probe A_23_P346969) were extracted 
from the microarray dataset. For survival analyses using 
mRNA values, values were grouped in tertiles, according 
to similarity in survival and considering the size of the 
subgroups and the number of events in each category. 
The CCP signature score was calculated as previously 
described [45] using the gene expression signature of 
31 CCP genes reported by Cuzick et al. [41]. For CCP 
analyses, mRNA values were further grouped in high and 
low, where the two lowest tertiles were defined as low, and 
the highest tertile was defined as high. Microarray data 
are publicly available at ArrayExpress (accession number 
E-MTAB-2532). Reverse phase protein array for PCNA 
protein levels was performed as previously described [45].
Statistical analyses
For clinical samples, statistical analyses were 
performed using the software package SPSS 22 (SPSS 
Inc, Chicago, IL) and significance was defined as p < 
0.05. Correlations between groups were evaluated using 
the Mann-Whitney U test for continuous variables. 
Survival analyses were done using the Kaplan-Meier 
(product-limit) method. Date of primary surgery was set 
as entry date and time of death due to endometrial cancer 
as endpoint (disease specific survival). Survival between 
groups was compared with log-rank test for trend. For cell 
lines data, Student’s unpaired t test with unequal variance 
was used.
Abbreviations
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